AQST Aquestive Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AQST

Price (delayed)

$3.985

Market cap

$292.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.13

Enterprise value

$380.8M

Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, ...

Highlights
Aquestive Therapeutics's quick ratio has surged by 119% YoY and by 27% QoQ
The EPS has surged by 88% year-on-year and by 35% since the previous quarter
AQST's equity is up by 10% year-on-year but it is down by 3.5% since the previous quarter
The debt has contracted by 8% YoY but it has grown by 2.8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://aquestive.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of AQST
Market
Shares outstanding
73.3M
Market cap
$292.11M
Enterprise value
$380.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.83
EV/EBIT
N/A
EV/EBITDA
322.17
EV/Sales
7.53
Earnings
Revenue
$50.58M
EBIT
-$163,000
EBITDA
$1.18M
Free cash flow
-$7.38M
Per share
EPS
-$0.13
Free cash flow per share
-$0.12
Book value per share
-$1.59
Revenue per share
$0.83
TBVPS
$0.92
Balance sheet
Total assets
$57.42M
Total liabilities
$163.91M
Debt
$112.57M
Equity
-$106.49M
Working capital
$22.66M
Liquidity
Debt to equity
-1.06
Current ratio
2.24
Quick ratio
1.77
Net debt/EBITDA
75.04
Margins
EBITDA margin
2.3%
Gross margin
58.8%
Net margin
-15.6%
Operating margin
-29.9%
Efficiency
Return on assets
-13.4%
Return on equity
N/A
Return on invested capital
-0.1%
Return on capital employed
-0.4%
Return on sales
-0.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AQST stock price

How has the Aquestive Therapeutics stock price performed over time
Intraday
-6.89%
1 week
1.66%
1 month
-9.02%
1 year
193.01%
YTD
97.28%
QTD
-6.46%

Financial performance

How have Aquestive Therapeutics's revenue and profit performed over time
Revenue
$50.58M
Gross profit
$29.75M
Operating income
-$15.1M
Net income
-$7.87M
Gross margin
58.8%
Net margin
-15.6%
The net margin has soared by 86% YoY and by 38% from the previous quarter
AQST's net income has surged by 86% year-on-year and by 35% since the previous quarter
Aquestive Therapeutics's operating margin has surged by 66% YoY and by 34% QoQ
The operating income has soared by 64% YoY and by 31% from the previous quarter

Growth

What is Aquestive Therapeutics's growth rate over time

Valuation

What is Aquestive Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
4.83
EV/EBIT
N/A
EV/EBITDA
322.17
EV/Sales
7.53
The EPS has surged by 88% year-on-year and by 35% since the previous quarter
AQST's equity is up by 10% year-on-year but it is down by 3.5% since the previous quarter
AQST's P/S is 159% above its last 4 quarters average of 2.0 and 125% above its 5-year quarterly average of 2.3
Aquestive Therapeutics's revenue has increased by 6% YoY and by 5% from the previous quarter

Efficiency

How efficient is Aquestive Therapeutics business performance
The company's return on invested capital has surged by 100% YoY and by 98% QoQ
The return on sales has surged by 100% year-on-year and by 98% since the previous quarter
AQST's ROA has soared by 86% year-on-year and by 35% since the previous quarter

Dividends

What is AQST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AQST.

Financial health

How did Aquestive Therapeutics financials performed over time
The company's total assets is 65% lower than its total liabilities
The current ratio has surged by 122% year-on-year and by 27% since the previous quarter
Aquestive Therapeutics's quick ratio has surged by 119% YoY and by 27% QoQ
AQST's equity is up by 10% year-on-year but it is down by 3.5% since the previous quarter
The debt has contracted by 8% YoY but it has grown by 2.8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.